Waters Corporation

NYSE:WAT Stok Raporu

Piyasa değeri: US$32.7b

Waters Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Waters şirketinin kazançları yıllık ortalama -3.1% oranında azalırken, Life Sciences sektörünün kazançları yıllık 3.8% oranında azalan oldu. Gelirler yıllık ortalama 3.9% oranında artan oldu. Waters şirketinin öz sermaye getirisi 2.9% olup, net marjı 11.9% dir.

Anahtar bilgiler

-3.10%

Kazanç büyüme oranı

-2.51%

EPS büyüme oranı

Life Sciences Sektör Büyümesi21.51%
Gelir büyüme oranı3.92%
Özkaynak getirisi2.94%
Net Marj11.93%
Son Kazanç Güncellemesi04 Apr 2026

Yakın geçmiş performans güncellemeleri

Analiz Makalesi • May 19

Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders

Investors weren't pleased with the recent soft earnings report from Waters Corporation ( NYSE:WAT ). We did some...

Recent updates

Analiz Makalesi • May 19

Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders

Investors weren't pleased with the recent soft earnings report from Waters Corporation ( NYSE:WAT ). We did some...
Anlatı Güncellemesi • May 18

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).
Anlatı Güncellemesi • May 01

WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside

Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).
Anlatı Güncellemesi • Apr 17

WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check

Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.
Anlatı Güncellemesi • Apr 03

WAT: New Four Division Model And Materials Focus Will Support Higher Profitability

Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).
Anlatı Güncellemesi • Mar 20

WAT: New Four Division Model Will Support Higher Long Term Profitability

Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.
Seeking Alpha • Mar 10

Waters: Doing Well, Acquired Activities Not So Much

Summary Waters' shares have retreated to the $300 level, presenting a renewed buying opportunity after initial post-acquisition gains evaporated. The $17.5B acquisition of Becton, Dickinson's Biosciences & Diagnostics Solutions expands Waters scale, though acquired business growth appears soft versus initial expectations. Waters guides 2026 sales to $6.405–$6.455B and adjusted EPS to $14.30–$14.50, reflecting early synergies and manageable leverage. At 21x earnings, Waters is not historically cheap, but synergy potential and deleveraging support a more upbeat outlook at current levels. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Mar 05

WAT: New Four Division Structure Will Support Higher Long Term Earnings

Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).
Anlatı Güncellemesi • Feb 19

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).
Anlatı Güncellemesi • Feb 05

WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists

Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).
Anlatı Güncellemesi • Jan 22

WAT: New Detector Launch And Stable Margins Will Support Future Upside

Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).
Anlatı Güncellemesi • Jan 08

WAT: Higher Margins And New Product Launch Will Support Future Upside

Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).
Analiz Makalesi • Jan 04

Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...
Anlatı Güncellemesi • Dec 25

WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism

Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).
Anlatı Güncellemesi • Dec 10

WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook

Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.
Anlatı Güncellemesi • Nov 26

WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends

Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.
Anlatı Güncellemesi • Nov 07

WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead

Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.
Anlatı Güncellemesi • Oct 23

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.
Anlatı Güncellemesi • Oct 09

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.
Analiz Makalesi • Sep 19

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...
Anlatı Güncellemesi • Sep 04

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.
Analiz Makalesi • Jul 24

Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Waters fair value estimate is US$465 Waters is estimated to be...
Analiz Makalesi • Jul 06

These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Feb 21

Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern

Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Weighing In On Waters Corporation: Facing A Valuation Headwind

Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

Waters Corp.: Embedded Expectations High Under Present Conditions

Summary Waters continues to present with high-quality business characteristics, including high returns on capital employed and loads of freely available cash. Embedded expectations remain exquisitely high, calling for outsized performance in a time when business returns may be contracting. Present multiples demand high compounding rate of operating capital, which reduces the margin of safety. Reiterate hold. Read the full article on Seeking Alpha
Seeking Alpha • May 24

Waters Corporation: Still Struggling A Bit

Summary Waters Corporation reported mediocre first quarter results with the top and bottom line declining. According to fiscal 2024 guidance, the company is still not expecting growth but due to the wide economic moat, we should be optimistic for long-term growth. At this point, Waters Corporation is fairly valued at best and still not a great investment. Read the full article on Seeking Alpha
Seeking Alpha • Mar 11

Waters Corporation: A Great (Share Price) Run

Summary Waters Corporation stock has seen strong momentum, rising over $100 per share in a short period of time. The company serves regulated markets with high-quality solutions and has a recurring revenue business model. After a tough 2023 and non-convincing outlook for 2024, I am surprised by the share price momentum, making me pleased to take profits in Waters Corporation stock here. Read the full article on Seeking Alpha

Gelir ve Gider Dağılımı

Waters nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:WAT Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
04 Apr 263,770450876244
31 Dec 253,165643745196
27 Sep 253,106648704196
28 Jun 253,046661686188
29 Mar 252,984657672185
31 Dec 242,958638673183
28 Sep 242,905623679180
29 Jun 242,877596669177
30 Mar 242,909604671177
31 Dec 232,956642691175
30 Sep 232,995653690179
01 Jul 232,992675696180
01 Apr 232,966689682178
31 Dec 222,972708658176
01 Oct 222,950697658171
02 Jul 222,901702645170
02 Apr 222,868705641171
31 Dec 212,786693627168
02 Oct 212,736695606165
03 Jul 212,671660563158
03 Apr 212,509616541144
31 Dec 202,365522555141
26 Sep 202,295504507138
27 Jun 202,278515524138
28 Mar 202,358537522143
31 Dec 192,407592526143
28 Sep 192,405577582144
29 Jun 192,406580584145
30 Mar 192,403591589144
31 Dec 182,420594585143
29 Sep 182,39255543140
30 Jun 182,38051550139
31 Mar 182,34227540136
31 Dec 172,30920545133
30 Sep 172,251548512130
01 Jul 172,212537501127
01 Apr 172,190533502127
31 Dec 162,167522512125
01 Oct 162,125498508121
02 Jul 162,099490509121
02 Apr 162,057467502119
31 Dec 152,042469493119
03 Oct 152,040469498119
04 Jul 152,032467496116

Kaliteli Kazançlar: WAT büyük bir tek seferlik zarar ile $168.0M, 4th April, 2026 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: WAT 'nin mevcut net kar marjları (11.9%) geçen yılın (22%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: WAT şirketinin kazançları son 5 yılda yılda 3.1% oranında azaldı.

Büyüme Hızlandırma: WAT 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: WAT geçtiğimiz yıl negatif kazanç büyümesine ( -31.6% ) sahipti ve bu da onu Life Sciences sektör ortalamasıyla ( 3.8% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: WAT 'nin Özsermaye Getirisi ( 2.9% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/20 12:00
Gün Sonu Hisse Fiyatı2026/05/20 00:00
Kazançlar2026/04/04
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Waters Corporation 39 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Catherine Ramsey SchulteBaird
Charles ButlerBarclays
Luke SergottBarclays